Back to News
Market Impact: 0.4
Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
Source: GlobeNewswire
Healthcare & BiotechCompany Fundamentals
A New Drug Application (NDA) is supported by positive results from the pivotal APEX trial in advanced systemic mastocytosis (AdvSM). The trial demonstrated clinically meaningful patient responses and evidence of disease modification, materially strengthening the drug's regulatory case and commercial outlook.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.70
More News
- Grab aims for 'next level' in financial services with purchase of buy-now pay-later platform Atome
- China's AI leaders keep quiet despite U.S. 'publicity' on tech risks
- Exclusive-Malaysia talks to rival airlines as it monitors AirAsia’s financial health, sources say
- Is Amazon Stock a Buy After Its Best Quarter in Years?
- Australia’s Reliance Worldwide agrees to Brookfield’s $2.9 billion buyout bid
- Trip.com swings to Q2 loss after $763 million antitrust penalty